Table 1 Baseline characteristics of the patients included

Age (years)

63.3 ± 9.9

62.9 ± 9.7

64.4 ± 10.2

0.040

Male gender (%)

151 (70.1)

112 (70.4)

39 (70.9)

0.948

Follow-up period (months)

11.1 ± 5.8

10.8 ± 5.4

12.1 ± 7.1

0.164

Length of stents (mm)

26.8 ± 5.6

26.4 ± 6.0

28.0 ± 4.3

0.034

Diameter of stents (mm)

3.1 ± 0.4

3.1 ± 0.4

2.9 ± 0.3

0.014

Complex lesion^a (%)

91 (42.5)

65 (40.9)

26 (47.2)

0.408

 Hypertension (%)

134 (62.6)

98 (61.6)

36 (65.5)

0.614

 Diabetes mellitus (%)

68 (31.8)

37 (23.3)

31 (56.4)

<0.001

 Total bilirubin (μmol/L)

12.4 ± 4.5

13.6 ± 4.4

8.9 ± 2.8

<0.001

 Direct bilirubin (μmol/L)

4.5 ± 1.8

4.9 ± 1.8

3.4 ± 1.3

<0.001

 Indirect bilirubin (μmol/L)

7.9 ± 2.9

8.7 ± 2.8

5.5 ± 1.7

<0.001

 Baseline RDW (%)

13.1 ± 0.8

13.0 ± 0.8

13.7 ± 0.8

<0.001

 RDW (%) at followup

13.4 ± 1.0

13.2 ± 0.8

14.0 ± 1.4

<0.001

 Hb (g/L)

137.3 ± 15.0

138.0 ± 14.6

135.4 ± 16.3

0.270

 Baseline WBC (10⁹/L)

7.7 ± 2.7

7.9 ± 2.8

7.3 ± 2.5

0.553

 WBC at followup (10⁹/L)

6.8 ± 1.8

6.7 ± 1.7

7.0 ± 2.0

0.267

 BUN (mmol/L)

6.0 ± 2.0

5.9 ± 1.9

6.3 ± 2.2

0.322

 eGFR (ml/min)

84.6 ± 23.6

84.5 ± 22.8

85.2 ± 26.1

0.849

 TG (mmol/L)

1.5 (1.2)*

1.6 (1.2)*

1.4 (1.3)*

0.476

 HDL-C (mmol/L)

1.0 ± 0.3

1.0 ± 0.3

1.0 ± 0.3

0.553

 LDL-C (mmol/L)

2.7 ± 1.0

2.7 ± 0.9

2.7 ± 1.2

0.867

 ACEI or ARB

142 (66.4)

108 (67.8)

34 (62.1)

0.570

 ß-Blocker

70 (32.6)

51 (32.2)

19 (34.5)

0.819

 Statin

186 (87.1)

139 (87.4)

47 (86.2)

0.873